Clinical Research Site
Excel is fully capable of conducting sponsored clinical research trials in the field of radio-pharmaceuticals and nuclear medicine procedures. All our research staff are GCP Trained and CITI certified consisting of highly trained, board-certified investigators, study coordinators, patient recruiters and support staff. At Excel, you will find areas designed to safely handle and administer radiopharmaceuticals, patient care areas, and physician interpretation resources.
The Excel Clinical Research Department (ECRD) is a dedicated department to assist investigators in their clinical trials. Our team is fully trained regarding rules and regulations of conducting human research, FDA requirements, and IRB compliance. We offer our expertise in conducting clinical research to a variety of academic institutions and pharmaceutical companies. Working closely with CRO’s & IRB, the ECRD team can conduct your sponsored clinical trials in the field of oncology radiopharmaceuticals.
At Excel Nuclear Oncology Center, Your clinical trials will be reviewed promptly, and budget will be provided in less than 2 weeks, in most cases. Excel is fully capable of conducting sponsored clinical research trials in the field of radiopharmacuticals and nuclear medicine procedures. All our research staff are GCP Trained and CITI certified consisting of highly trained, board certified investigators, study coordinators, patient recruiters and support staff. At Excel, you will find areas designed to safely handle and administer radiopharmaceuticals, patient care areas, and physician interpretation resources.
Excel with its broad oncology network can expedite Subject recruitment for your clinical trials. Our ECRD team has high experience and track record in clinical research Project coordination, Technologist training, and Management of data and report forms. Our regulatory department is in full compliance with FDA, GCP, ICH and IRB guidelines. Our highly trained and efficient staff deliver exceptional levels of service completed with the utmost professionalism and provide sponsors with reliable, quality data.
Therapy
ClinicalTrials.gov ID NCT07611110
Conditions:
Metastatic Castration-resistant Prostate Cancer
Detailed Description:
Approximately 670 adult participants with mCRPC will be randomized to receive either AZD2265 or standard of care treatment (investigator’s choice of cabazitaxel, ARPI switch, or radium-223). They will receive their assigned treatment until disease progression, unacceptable toxicity, or other discontinuation criteria are met. Tumor evaluation scans will continue after treatment discontinuation until radiographically confirmed progression or death.
For more information about this clinical trial, please visit ClinicalTrials.gov and search for ClinicalTrials.gov Identifier: NCT07611110
ClinicalTrials.gov ID NCT07505771
Sponsor Immunome, Inc.
Conditions:
Solid Malignancies
Detailed Description:
IM-3050-101 is a 2-part Phase 1 first-in-human (FIH), open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, dosimetry, pharmacokinetics (PK), and preliminary anti-tumor activity of the radiopharmaceutical 177Lu-IM-3050 in participants with FAP-expressing advanced solid tumors.
For more information about this clinical trial, please visit ClinicalTrials.gov and search for ClinicalTrials.gov Identifier: NCT07505771
ClinicalTrials.gov ID NCT07197645
Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Conditions:
Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
Detailed Description:
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx (153SmDOTMP) in patients with painful bone metastases.
For more information about this clinical trial, please visit ClinicalTrials.gov and search for ClinicalTrials.gov Identifier: NCT07197645
Call Now for Info on Active Clinical Trials
Susan Cork
Therapy Coordinator
Main Line: 713-781-6200 x3203
Direct Line: 713.341.3203
Fax: 713-781-6206